Table 2 Demographic data of HER2+ patients with preserved EF versus decreased EF following TRA exposure

Total Number, n (%)

127

114 (89.0)

13 (11.3)

–

–

–

Age (years, mean ± SD)

57 ± 11

57 ± 11

55 ± 10

–

–

0.72

BMI (kg/m², mean ± SD)

32 ± 8

32 ± 12

32 ± 8

–

–

1.0

 Black

64 (50)

57 (50.4)

7 (50)

1.0

0.3–2.8

1.0

 White

59 (46)

52 (45.1)

7 (50)

1.19

0.4–3.3

0.75

 Hispanic

5 (4)

5 (4.4)

–

–

–

–

 ER−/PR-

55 (43)

51 (44)

4 (28)

0.49

0.15–1.66

0.25

 ER−/PR+

1 (0.8)

1 (0.8)

–

–

–

–

 ER+/PR-

25 (19)

23 (20)

2 (14)

0.66

0.14–3.15

0.60

 ER+/PR+

47 (37)

39 (34)

8 (57)

2.56

0.83–7.91

0.10

 I

34 (27)

32 (28)

2 (14)

0.43

0.09–2.01

0.28

 II

59 (45)

51 (45)

8 (57)

1.64

0.53–5.05

0.38

 III

18 (12)

17 (13)

1 (7)

0.44

0.05–3.57

0.44

 IV

17 (13)

14 (12)

3 (21)

1.94

0.48–7.85

0.34

 AC ➔ TRA

40 (31)

34 (30)

6 (43)

1.76

0.5–5.5

0.32

 Non-AC ➔ TRA

88 (68)

80 (70)

8 (57)

0.56

0.2–1.7

0.32

 Baseline (mean ± SD)

64 ± 7

64 ± 7

62 ± 9

–

–

0.16

 Median Decrease

 3 months

–

1 ± 7

10 ± 0

–

–

–

 6 months

–

3 ± 6

10 ± 10

–

–

–

 9 months

–

4 ± 11

17 ± 9

–

–

–

 Arrhythmia

6 (5)

4 (4)

2 (15)

4.58

0.76–27.7

0.09

 CAD

8 (6)

6 (5)

2 (15)

3.0

0.54–16.5

0.21

 DM

32 (25)

28 (25)

4 (31)

1.22

0.36–4.22

0.74

 HTN

78 (61)

69 (61)

9 (69)

1.17

0.37–3.73

0.78

 Smoker

46 (36)

38 (33)

8 (57)

2.67

0.86–8.24

0.08

 Alcohol

23 (18)

21 (18)

2 (14)

0.73

0.15–3.55

0.70

 Anti-RAAS

49

47 (32.4)

2 (23)

0.26

0.05–1.22

0.06

 BB

24

20 (17.5)

2 (30.7)

0.85

0.17–4.17

0.84

 CCB

22

20 (17.5)

2 (15.4)

0.85

0.17–4.17

0.84

 Loop diuretic

16

15 (13.1)

1 (7.7)

0.55

0.07–4.50

0.58

 Thiazide diuretic

31

29 (25.4)

2 (15.4)

0.48

0.11–2.54

0.37

 Statin

25

23 (20.2)

2 (15.4)

0.65

0.15–3.47

0.60